tremelimumab astrazeneca
astrazeneca ab - tremelimumab - carcinoma, non-small-cell lung - antineoplastic agents - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
zolacos cp
astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin; ; bicalutamide 50mg - combination - 10.8mg+50mg pack - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin excipient: polyglactin active: bicalutamide 50mg excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.
zolacos cp
astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin; ; bicalutamide 50mg; - combination - 3.6mg + 50mg pack - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin excipient: polyglactin active: bicalutamide 50mg excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.
zoladex 3.6mg
astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin; - injection (depot) - 3.6 mg - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin excipient: polyglactin - zoladex 3.6 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.
cosudex
astrazeneca limited - bicalutamide 150mg - film coated tablet - 150 mg - active: bicalutamide 150mg excipient: hypromellose lactose monohydrate macrogol 300 magnesium stearate povidone purified water sodium starch glycolate titanium dioxide
faslodex
astrazeneca limited - fulvestrant 50 mg/ml; - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml excipient: benzyl alcohol benzyl benzoate castor oil ethanol - faslodex is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: - not previously treated with endocrine therapy, or - previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.
zoladex 10.8mg
astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin; - injection (depot) - 10.8 mg - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin excipient: polyglactin - zoladex 10.8 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.
bricanyl turbuhaler
astrazeneca limited - terbutaline sulfate 0.25mg; terbutaline sulfate 200ug equivalent to 0.25 mg metered dose - powder for inhalation - 0.25 mg/dose - active: terbutaline sulfate 0.25mg terbutaline sulfate 200ug equivalent to 0.25 mg metered dose excipient: lactose monohydrate - relief of bronchospasm occurring in bronchial asthma, bronchitis and other bronchopulmonary conditions where bronchospasm is a complicating factor. acute prophylaxis in situations known to induce bronchospasm, e.g. exercise induced asthma.
bricanyl turbuhaler
astrazeneca limited - terbutaline sulfate 0.5mg - powder for inhalation - 0.5 mg/dose - active: terbutaline sulfate 0.5mg
astrazeneca water for injections 10ml ampoule
astrazeneca pty ltd - water for injections -